- Home
- PRVA
as 07-26-2024 4:00pm EST
Privia Health Group Inc is a technology-driven, national physician-enablement company. It collaborates with medical groups, health plans, and health systems to optimize physician practices, improve patient experiences, and reward doctors for delivering high-value care in both in-person and virtual care settings.
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | ARLINGTON |
| Market Cap: | 2.1B | IPO Year: | 2021 |
| Target Price: | $24.09 | AVG Volume (30 days): | 729.0K |
| Analyst Decision: | Buy | Number of Analysts: | 11 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.16 | EPS Growth: | 23.08 |
| 52 Week Low/High: | $15.92 - $28.10 | Next Earning Date: | 08-08-2024 |
| Revenue: | $1,686,704,000 | Revenue Growth: | 18.02% |
| Revenue Growth (this year): | 75.72% | Revenue Growth (next year): | 12.36% |
Stock Insider Trading Activity of Privia Health Group Inc. (PRVA)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Boehler Adam | PRVA | Director | Jun 11 '24 | Buy | $16.50 | 364 | $6,006.00 | 5,773,522 | SEC Form 4 |
| Boehler Adam | PRVA | Director | May 29 '24 | Buy | $16.50 | 5,306 | $87,549.00 | 5,773,158 | SEC Form 4 |
| Boehler Adam | PRVA | Director | May 24 '24 | Buy | $16.49 | 4,280 | $70,577.20 | 5,767,852 | SEC Form 4 |
| McCarthy Thomas A | PRVA | Director | May 22 '24 | Buy | $16.37 | 10,000 | $163,700.00 | 52,611 | SEC Form 4 |
| Boehler Adam | PRVA | Director | May 21 '24 | Buy | $16.17 | 277,565 | $4,488,226.05 | 5,488,701 | SEC Form 4 |
| Boehler Adam | PRVA | Director | May 21 '24 | Buy | $16.43 | 102,229 | $1,679,622.47 | 5,590,930 | SEC Form 4 |
| Boehler Adam | PRVA | Director | May 21 '24 | Buy | $16.28 | 172,642 | $2,810,611.76 | 5,763,572 | SEC Form 4 |
| Bartrum Thomas | PRVA | May 10 '24 | Sell | $17.88 | 1,506 | $26,927.28 | 102,356 | SEC Form 4 | |
| Mountcastle David | PRVA | EVP & Chief Financial Officer | May 10 '24 | Sell | $17.88 | 2,232 | $39,908.16 | 257,727 | SEC Form 4 |
| Mehrotra Parth | PRVA | Chief Executive Officer | May 10 '24 | Sell | $17.88 | 13,869 | $247,977.72 | 247,771 | SEC Form 4 |
| Morris Matthew Shawn | PRVA | Director | Apr 30 '24 | Sell | $18.42 | 11,059 | $203,706.78 | 70,101 | SEC Form 4 |
| Bartrum Thomas | PRVA | Apr 30 '24 | Sell | $18.42 | 2,252 | $41,481.84 | 103,862 | SEC Form 4 | |
| Mountcastle David | PRVA | EVP & Chief Financial Officer | Apr 30 '24 | Sell | $18.42 | 2,320 | $42,734.40 | 259,959 | SEC Form 4 |
| Mehrotra Parth | PRVA | Chief Executive Officer | Apr 30 '24 | Sell | $18.42 | 12,219 | $225,073.98 | 261,640 | SEC Form 4 |
| Mountcastle David | PRVA | EVP & Chief Financial Officer | Apr 2 '24 | Sell | $17.77 | 3,933 | $69,889.41 | 262,279 | SEC Form 4 |
| Sullivan William M | PRVA | Director | Mar 8 '24 | Sell | $23.03 | 7,115 | $163,858.45 | 5,445,418 | SEC Form 4 |
| Sullivan William M | PRVA | Director | Mar 8 '24 | Sell | $23.02 | 400 | $9,208.00 | 5,445,018 | SEC Form 4 |
| Sullivan William M | PRVA | Director | Jan 24 '24 | Sell | $23.03 | 9,951 | $229,171.53 | 5,464,533 | SEC Form 4 |
| Sullivan William M | PRVA | Director | Jan 24 '24 | Sell | $23.13 | 12,000 | $277,560.00 | 5,452,533 | SEC Form 4 |
| Sullivan William M | PRVA | Director | Dec 28 '23 | Sell | $23.97 | 12,000 | $287,640.00 | 5,474,484 | SEC Form 4 |
| Sullivan William M | PRVA | Director | Dec 13 '23 | Sell | $23.08 | 12,000 | $276,960.00 | 5,498,484 | SEC Form 4 |
| Sullivan William M | PRVA | Director | Dec 13 '23 | Sell | $24.00 | 12,000 | $288,000.00 | 5,486,484 | SEC Form 4 |
Latest Privia Health Group Inc. News
PRVA Breaking Stock News: Dive into PRVA Ticker-Specific Updates for Smart Investing
Argus Research
3 days ago
PRVA: Raising target price to $21.00
Argus Research
10 days ago
PRVA: Raising target price to $20.00
GlobeNewswire
16 days ago
Privia Health to Report Second Quarter 2024 Results on Thursday, August 8
Argus Research
17 days ago
PRVA: Rating increased to a HOLD
MT Newswires
17 days ago
Evercore ISI Lowers Price Target on Privia Health to $20 From $23, Maintains Outperform Rating
Simply Wall St.
23 days ago
Should Weakness in Privia Health Group, Inc.'s (NASDAQ:PRVA) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
GlobeNewswire
a month ago
Privia Receives HFMA’s MAP Award for High Performance in Revenue Cycle for Performance Year 2023
Simply Wall St.
2 months ago
Insider Stock Buying Reaches US$9.30m On Privia Health Group
Compare PRVA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PRVA Privia Health Group Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.